Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neoadjuvant BKM120 in High-risk Prostate Cancer
NCT01695473 · Won Kim · PHASE2 · terminated · last registry update 2021-01-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of Accrual” | – | Registry record, Won Kim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3R1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-11Also stopped (terminated): Prince of Songkla University, BKM120 (NCT01806649)
- 2021-10-07Results posted on the registry: Pfizer, PF-05212384 (gedatolisib) + Docetaxel (NCT01920061)
- 2021-06-23Results posted on the registry: Restorbio Inc., Dactolisib (NCT04668352)
- 2021-06-21Results posted on the registry: Memorial Sloan Kettering Cancer Center, Buparlisib (NCT01551030)
- 2021-02-10Also stopped (terminated): Restorbio Inc., RTB101 + Placebo (NCT04409327)
- 2020-12-19Also stopped (terminated): Novartis Pharmaceuticals, INC424 + BKM120 (NCT01730248)
- 2020-12-16Phase 3 first posted: Restorbio Inc., Dactolisib (NCT04668352)
- 2020-12-08Also stopped (terminated): Novartis Pharmaceuticals, BEZ235 + Paclitaxel (NCT01495247)
- 2020-10-28Results posted on the registry: SOLTI Breast Cancer Research Group, BKM120 (NCT01629615)
- 2020-10-27Results posted on the registry: University of Chicago, PI3K inhibitor BKM120 + cetuximab (NCT01816984)
- 2020-06-18Results posted on the registry: Novartis Pharmaceuticals, Fulvestrant + BKM120 (NCT01610284)
- 2020-05-07Results posted on the registry: Vanderbilt-Ingram Cancer Center, Enzalutamide + Taselisib (NCT02457910)
- 2020-04-28Also stopped (withdrawn): Abramson Cancer Center at Penn Medicine, Hydroxychloroquine (HCQ) + Gedatolisib (NCT03400254)
- 2020-04-08Phase 3 first posted: Adlai Nortye Biopharma Co., Ltd., Buparlisib & Paclitaxel (NCT04338399)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision